Healthcare
The Oncology Institute, Inc.(TOI)
Live Price
Offline$5.26
+0.19% today
1Y Change
+131.88%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $400.00M
- Revenue Growth
- +27.8%
- EPS Growth
- +23.9%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
The Oncology Institute, Inc. (TOI) is a Healthcare stock with a market cap of $400.00M and listed on NASDAQ. The stock last traded around $5.26 and up 131.9% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +27.8%, EPS growth of +23.9%, a dividend yield of 0.0%. What stands out right now is revenue +27.8%, EPS +23.9%, free cash flow +8.4% with operating margin -7.2% and ROIC -35.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TOI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+27.8% vs +7.6% peer median
Operating Margin
Below sector median
-7.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +27.8% and EPS at +23.9%, with operating margin around -7.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +14.4% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | -1.0% | +2.9% | +25.7% |
2026 Mar 12, 2026 | +25.0% | +8.4% | +35.1% | +17.6% |
2025 Nov 13, 2025 | -16.7% | +28.9% | +5.2% | +22.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TOI
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TOI Max Drawdown
-49.79%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TOI and SPY.
Company Overview
The Oncology Institute, Inc.
NASDAQ Capital Market
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
- Leadership
- Daniel Virnich
- IPO Date
- Jun 4, 2020
- Employees
- 825
- Street Address
- 18000 Studebaker Road
- Mailing
- Cerritos, CA, 90703
- Region
- Cerritos, CA, US
- Reporting Currency
- USD
- Investor Line
- 213 760 1328
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.8
- Price/Book
- โ
Growth
- Revenue
- +27.8%
- EPS
- +23.9%
- Free Cash Flow
- +8.4%
Profitability
- Gross Margin
- 13.8%
- Operating Margin
- -7.2%
- Net Margin
- -12.1%
- ROE
- 759.7%
- ROIC
- -35.7%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 1.59
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.